



ASX ANNOUNCEMENT

Actinogen announces strategic collaboration with Oxford University researchers

Sydney 7 December 2021. Actinogen Medical ASX:ACW (“ACW” or “the Company”) is pleased to announce finalisation of a clinical protocol as part of its strategic collaboration with researchers at the Radcliffe Department of Medicine, University of Oxford, to investigate Xanamem® and a condition called Mild Autonomous Cortisol Secretion (MACS). MACS is associated with over-production of the stress hormone cortisol, by non-cancerous growths on the adrenal glands. Actinogen is supplying Xanamem to Oxford free-of-charge and providing trial design support.

Actinogen will collaborate with Professor Jeremy Tomlinson and the Oxford University Centre for Diabetes, Endocrinology & Metabolism, to investigate the therapeutic potential for Xanamem in patients with MACS in an investigator-sponsored clinical trial of 12 weeks treatment, funded by a Medical Research Council (UK) grant. The placebo-controlled trial will enroll approximately 40 participants and evaluate effects of Xanamem on metabolism, bone density, and cognitive function. Final results are anticipated in 2024.

Dr Steve Gourlay, the Company’s CEO and Managing Director said “The MACS collaboration represents an important opportunity to investigate the potential benefits of Xanamem on the cortisol system outside of the brain. We are pleased to be working with Oxford University, an academic centre of excellence in this area.”

Professor Jeremy Tomlinson, Chief Investigator of the MACS study commented “This is a hugely important clinical problem and currently there are no licenced treatments. This study may not only provide a detailed understanding of the processes that drive the condition, but also offer potential for an entirely novel treatment.”

ENDS

Investors

Dr. Steven Gourlay
CEO & Managing Director
P: +61 2 8964 7401
E. steven.gourlay@actinogen.com.au

Michael Roberts
Investor Relations
P: +61 2 8964 7401
E. michael.roberts@actinogen.com.au

Media

Randal Killip
Profile for Media
M: +61 425 714 159
E. randal@profileformedia.com.au

Announcement authorised by the Board of Directors of Actinogen Medical

About Mild Autonomous Cortisol Secretion (MACS)

MACS is an increasingly diagnosed condition associated with over-production of the stress hormone cortisol, caused by benign, non-cancerous growths (known as adenomas) on the adrenal glands. MACS manifests typically in a subset of elderly patients and has an estimated prevalence of 3% of the population aged over seventy years of age. The chronically raised cortisol associated with MACS has severe effects on many tissues and is associated with insulin resistance and poor bone health, as well as increased cardiovascular events, increased frailty, and mortality. Surgical removal of adenomas is currently the only therapeutic option for clinicians and their patients, and is associated with significant risks and costs. Often surgical resection is inappropriate, but there are currently no licenced pharmacological treatments for MACS and no clinical consensus as to optimal management of this condition.

About Actinogen Medical

Actinogen Medical (ACW) is an ASX-listed, biotechnology company developing a novel therapy for neurological diseases associated with dysregulated brain cortisol. There is a strong association between cortisol and detrimental changes in the brain, affecting cognitive function, harm to brain cells and long-term cognitive health.

Cognitive function means how a person understands, remembers and thinks clearly. Cognitive functions include memory, reasoning, awareness and decision-making, and to a large extent, influence our personality.

We are currently developing our lead compound, Xanamem®, as a promising new therapy for Alzheimer's Disease, Fragile X Syndrome, Depression and other neurological diseases where reducing cortisol inside brain cells could have a positive impact. The cognitive dysfunction, behavioural abnormalities, and neuropsychological burden associated with these conditions is debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

About Xanamem®

Xanamem's novel mechanism of action works by blocking the production of intracellular cortisol through the inhibition of the 11 β -HSD1 enzyme in the brain. Xanamem is designed to get into the brain after it is absorbed in the intestines upon swallowing its capsule.

Chronically elevated cortisol is associated with cognitive decline in Alzheimer's Disease, potentially linked to cognitive impairment and anxiety in Fragile X Syndrome, and cognitive impairment in Depression and other diseases.

The Company has studied 11 β -HSD1 inhibition by Xanamem in more than 250 volunteers and patients, so far finding a statistically significant improvement in cognition over placebo in healthy, older volunteers. A series of Phase 2 studies in multiple diseases is being conducted to further confirm and characterise Xanamem's therapeutic potential.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority. Xanamem® is a trademark of Actinogen Medical.

Disclaimer

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies, and regulatory and clinical development risks and uncertainties) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

ACTINOGEN MEDICAL ENCOURAGES ALL CURRENT INVESTORS TO GO PAPERLESS BY REGISTERING THEIR DETAILS WITH THE DESIGNATED REGISTRY SERVICE PROVIDER, AUTOMIC GROUP.